Details
Stereochemistry | ACHIRAL |
Molecular Formula | C16H15N7O |
Molecular Weight | 321.3366 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC(CN2N=NC3=C2N=C(N)N=C3C4=CC=CO4)=CC=C1N
InChI
InChIKey=HQSBCDPYXDGTCL-UHFFFAOYSA-N
InChI=1S/C16H15N7O/c1-9-7-10(4-5-11(9)17)8-23-15-14(21-22-23)13(19-16(18)20-15)12-3-2-6-24-12/h2-7H,8,17H2,1H3,(H2,18,19,20)
Vipadenant (V2006) is a small molecule, adenosine A2A receptor antagonist that was being investigated in Parkinson's disease. Due to safety concerns development ceased in 2010 and the rights were regained from Biogen Idec in 2011 with no further investment made. In October 2014, RedoxTherapies licensed Vipadenant as it has the potential to disrupt an immunosuppressive mechanism of tumour protection, generating improved efficacy for immunotherapies of certain cancers when used in combination with other drugs.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20375654
Healthy volunteers: daily oral vipadenant (2.5-100 mg/d for 10 or 11 days)
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C38149
Created by
admin on Sat Dec 16 17:49:27 GMT 2023 , Edited by admin on Sat Dec 16 17:49:27 GMT 2023
|
||
|
NCI_THESAURUS |
C2139
Created by
admin on Sat Dec 16 17:49:27 GMT 2023 , Edited by admin on Sat Dec 16 17:49:27 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
9329
Created by
admin on Sat Dec 16 17:49:27 GMT 2023 , Edited by admin on Sat Dec 16 17:49:27 GMT 2023
|
PRIMARY | |||
|
LDR3USH1NJ
Created by
admin on Sat Dec 16 17:49:27 GMT 2023 , Edited by admin on Sat Dec 16 17:49:27 GMT 2023
|
PRIMARY | |||
|
442908-10-3
Created by
admin on Sat Dec 16 17:49:27 GMT 2023 , Edited by admin on Sat Dec 16 17:49:27 GMT 2023
|
PRIMARY | |||
|
CHEMBL3545386
Created by
admin on Sat Dec 16 17:49:27 GMT 2023 , Edited by admin on Sat Dec 16 17:49:27 GMT 2023
|
PRIMARY | |||
|
CHEMBL447664
Created by
admin on Sat Dec 16 17:49:27 GMT 2023 , Edited by admin on Sat Dec 16 17:49:27 GMT 2023
|
PRIMARY | |||
|
C152892
Created by
admin on Sat Dec 16 17:49:27 GMT 2023 , Edited by admin on Sat Dec 16 17:49:27 GMT 2023
|
PRIMARY | |||
|
DTXSID90196103
Created by
admin on Sat Dec 16 17:49:27 GMT 2023 , Edited by admin on Sat Dec 16 17:49:27 GMT 2023
|
PRIMARY | |||
|
1148126-34-4
Created by
admin on Sat Dec 16 17:49:27 GMT 2023 , Edited by admin on Sat Dec 16 17:49:27 GMT 2023
|
SUPERSEDED | |||
|
300000034483
Created by
admin on Sat Dec 16 17:49:27 GMT 2023 , Edited by admin on Sat Dec 16 17:49:27 GMT 2023
|
PRIMARY | |||
|
WW-153
Created by
admin on Sat Dec 16 17:49:27 GMT 2023 , Edited by admin on Sat Dec 16 17:49:27 GMT 2023
|
PRIMARY | |||
|
21874557
Created by
admin on Sat Dec 16 17:49:27 GMT 2023 , Edited by admin on Sat Dec 16 17:49:27 GMT 2023
|
PRIMARY | |||
|
874193-81-4
Created by
admin on Sat Dec 16 17:49:27 GMT 2023 , Edited by admin on Sat Dec 16 17:49:27 GMT 2023
|
SUPERSEDED | |||
|
DB06625
Created by
admin on Sat Dec 16 17:49:27 GMT 2023 , Edited by admin on Sat Dec 16 17:49:27 GMT 2023
|
PRIMARY |
ACTIVE MOIETY